Ferndale-based pharmaceutical company Eloquest Healthcare has recently received pre-market clearance from the U.S. Food and Drug Administration on the line of post-operative dressings they created in partnership with Vancive Medical Technologies (VMT).
The new dressings, called ReliaTect, incorporate BeneHold CHG—an adhesive technology from VMT that comfortably secures the dressing to the skin, absorbs fluids, and protects the site from external contaminants.
The CHG contained within the adhesive preserves the dressings from microbial growth, making them ideally suited for post-operative sites. Eloquest Healthcare is the exclusive distributor of the dressings in the United States and Canada.
“The unique characteristics of the ReliaTect post-operative dressings make them a great complement to our growing portfolio and increases the value we are able to provide to our customers,” says Tim O’Halla, president and CEO for Eloquest Healthcare. “The BeneHold CHG adhesive technology delivers the combination of fluid management and sustained transparency with antimicrobial effect of chlorhexidine gluconate, offering clinicians a simple and innovative solution for post-op site management.”
The ReliaTect dressings will be available in two sizes, small and large.
“BeneHold CHG adhesive technology adds value to post-operative dressings,” says Kirsten Newquist, general manager for VMT. “The collaboration with Eloquest Healthcare brings together complementary resources, experience, and expertise from each company. We look forward to working with Eloquest Healthcare to bring ReliaTect to market.”